Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Aug;69(4):318–333. doi: 10.1016/j.curtheres.2008.08.006

Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study

Xing Zeng 1, Yi Feng 1, Liu Yang 1, Yu Huang 1, Dan Zhou 1, Jing Sun 1, Yiming Liu 1,*, Yuanhui Deng 1,*
PMCID: PMC3969939  PMID: 24692809

Abstract

Background: Genistein capsules are currently being developed to treat osteoporosis in China. Genistein is extracted from the fruit of Sophora japonica Leguminosae.

Objective: The objective of this study was to assess the pharmacokinetics of genistein capsules after single and multiple oral doses in healthy Chinese subjects.

Methods: This was a Phase I, randomized, open-label, single- and multiple- dose study in healthy Chinese adults (aged 19–40 years). In the single-dose study, subjects were randomly assigned in a 1:1:1 ratio to receive genistein 50, 100, or 300 mg (in 50-mg capsules). To assess the effect of food on the pharmacokinetics, subjects in the 50-mg group were equally randomized again into fasting and postprandial (genistein was administered after a high-fat breakfast) groups according to a 2-way cross-over design. A separate equal-sized group of subjects were administered genistein 50 mg on day 1 (single dose), received no treatment on days 2 and 3, and were administered genistein 50 mg QD for 6 days (days 4–9) to obtain a multiple-dose pharmacokinetic profile. Because genistein is converted so rapidly and completely to glucuronidated genistein after administration, plasma concentrations of glucuronidated genistein were determined using a validated high-performance liquid chromatography/ tandem mass spectrometry method. Drug tolerability was assessed by monitoring adverse events (AEs) and laboratory parameters.

Results: The study enrolled 40 healthy subjects (24 men, 16 women; 10 each in the 50-, 100-, and 300-mg single-dose groups and 10 in the multiple-dose group). Three subjects voluntarily withdrew (2 in the 100-mg group and 1 in the 300-mg group) before study drug administration. Thirty-seven subjects (24 men, 13 women) completed the study and were included in the analysis. The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0−t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h−1; and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL. The plasma glucuronidated genistein concentrations were directly proportional to the administered dose over the range of 50 to 100 mg and increased nonproportionately with the 300-mg dose. No statistically significant differences in pharmacokinetic parameters were found in the fasting group compared with the postprandial group. In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0−t, 2830 [1541] vs 2078 [1308] ng/mL · h−1; Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL). All AEs were assessed as mild or moderate and resolved without treatment, with the exception of elevated alanine aminotransferase and aspartate aminotransferase activities in one subject that resolved with treatment.

Conclusions: The pharmacokinetics of glucuronidated genistein appeared to fit the linear-dose range of genistein 50 to 100 mg, but not the 300-mg dose in these healthy Chinese volunteers. Food consumption did not significantly affect the pharmacokinetic properties. No significant differences were observed in the pharmacokinetic parameters after multiple doses of genistein compared with a single dose, suggesting that the drug did not accumulate after multiple doses.

Key Words: pharmacokinetics, genistein capsule, single dose, multiple dose, healthy Chinese subject

Full Text

The Full Text of this article is available as a PDF (852.0 KB).

Contributor Information

Yiming Liu, Email: lyming2000@163.com.

Yuanhui Deng, Email: yhdeng62@126.com.

References

  • 1.Arjmandi BH, Smith BJ. Soy isoflavones' osteoprotective role in postmenopausal women: Mechanism of action. J Nutr Biochem. 2002;13:130–137. doi: 10.1016/s0955-2863(02)00172-9. [DOI] [PubMed] [Google Scholar]
  • 2.Li XH, Zhang JC, Xiao PG. Mechanism of soy isoflavone against osteoporosis. World Phytomedicines. 2006;21:1–5. [in Chinese] [Google Scholar]
  • 3.Anupongsanugool E, Teekachunhatean S, Rojanasthien N. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of sW beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin Pharmacol. 2005;5:2. doi: 10.1186/1472-6904-5-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Anderson GL, Limacher M, Assaf AR, Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized contrdled trial. JAVA. 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701. [DOI] [PubMed] [Google Scholar]
  • 5.Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190:1141–1167. doi: 10.1016/j.ajog.2003.09.033. [DOI] [PubMed] [Google Scholar]
  • 6.Warren MP, Shortle B, Dominguez J. Use of alternative therapies in menopause. Best Pract Res Clin Obstet Gynecol. 2002;16:411–448. doi: 10.1053/beog.2002.0290. [DOI] [PubMed] [Google Scholar]
  • 7.Gao JC, Zhang JC, Chen Y. Chemical classification and pharmacdogy of phytoestrogen. World Phytomedicines. 2006;21:231–237. [in Chinese] [Google Scholar]
  • 8.Fanti P, Monier-Faugere MC, Geng Z. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int. 1998;8:274–281. doi: 10.1007/s001980050065. [DOI] [PubMed] [Google Scholar]
  • 9.Gao YH, Yamaguchi M. Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol. 1999;58:767–772. doi: 10.1016/s0006-2952(99)00162-8. [DOI] [PubMed] [Google Scholar]
  • 10.Yamaguchi M, Gao YH. Inhibitory effect of genistein on bone resorption in tissue culture. Biochem Pharmacol. 1998;55:71–76. doi: 10.1016/s0006-2952(97)00402-4. [DOI] [PubMed] [Google Scholar]
  • 11.Song T, Barua K, Buseman G, Murphy PA. Soy isoflavone analysis: Quality control and a new internal standard. Am J Clin Nutr. 1998;68(Suppl 6):1474S–1479S. doi: 10.1093/ajcn/68.6.1474S. [DOI] [PubMed] [Google Scholar]
  • 12.Zhang Y, Hendrich S, Murphy PA. Glucuronides are the main isoflavone metabolites in women. J Nutr. 2003;133:399–404. doi: 10.1093/jn/133.2.399. [DOI] [PubMed] [Google Scholar]
  • 13.Chen J, Lin H, Hu M. Absorption and metabdism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol. 2005;55:159–169. doi: 10.1007/s00280-004-0842-x. [DOI] [PubMed] [Google Scholar]
  • 14.Sfakianos J, Coward L, Kirk M, Barnes S. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J Nutr. 1997;127:1260–1268. doi: 10.1093/jn/127.7.1260. [DOI] [PubMed] [Google Scholar]
  • 15.Wang ZL, Sun JY, Wang DN. Structural identification ofgenistein from huaijiao and its pharmacology in preventive osteoporosis. Chin Pharmacol Bull. 2004;20:580–584. [in Chinese] [Google Scholar]
  • 16.Sun JY, Wang SW, Xie YH. The effect of genistein on bone mass density and trace elements in retinoic acid-induced model rats. Northwest Pharm J. 2003;18:110–113. [in Chinese] [Google Scholar]
  • 17.Sun JY, Xie YH, Shi XY. Comparative research of genistein capsule on substance of bone metabolism in osteoporosis rats. Chin J Comparative Med. 2003;13:146–149. [in Chinese] [Google Scholar]
  • 18.Zhou SY, Mei QB, Wang RT. Dose-dependent pharmacokinetic study of genistein in Beagle dogs. Yao Xue Xue Bao. 2005;40:553–556. [in Chinese] [PubMed] [Google Scholar]
  • 19.Wang QW, Mei QB, Zhou SY. Study on the bioavailability ofgenistein capsule in SD rats. Pharm J Chin PEA. 2003;19:189–192. [in Chinese] [Google Scholar]
  • 20.Zhou SY, Liu XY, Teng ZH. Biliary excretion of genistein and its metabolite at different doses in rats. Yao Xue Xue Bao. 2006;41:752–755. [in Chinese] [PubMed] [Google Scholar]
  • 21.Liu CX. Practice Pharmacokinetics. Chinese Medicine Technology Publishing Company; Beijing, China: 2003. pp. 2–10. [Google Scholar]
  • 22.Li P, Chen XY, Dai XJ. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans. J Chromatogr B. 2007;852:479–484. doi: 10.1016/j.jchromb.2007.02.013. [DOI] [PubMed] [Google Scholar]
  • 23.Park K, Kim YS, Kwon K. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in heathy Korean adults. Clin Ther. 2007;29:154–162. doi: 10.1016/j.clinthera.2007.01.016. [DOI] [PubMed] [Google Scholar]
  • 24.Setchell KD, Faughnan MS, Avades T. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77:411–419. doi: 10.1093/ajcn/77.2.411. [DOI] [PubMed] [Google Scholar]
  • 25.Joshi JV, Vaidaya RA, Pandey SN. Plasma levels of genistein following a single dose of soy extract capsule in Indian women. Indian J Med Res. 2007;125:534–541. [PubMed] [Google Scholar]
  • 26.Shelnutt SR, Cimino CO, Wiggins PA. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr. 2002;76:588–594. doi: 10.1093/ajcn/76.3.588. [DOI] [PubMed] [Google Scholar]
  • 27.Setchell KD, Brown NM, Desai P. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131(Suppl 4):1362S–1375S. doi: 10.1093/jn/131.4.1362S. [DOI] [PubMed] [Google Scholar]
  • 28.Setchell KD. Absorption and metabolism of soy isoflavones: From food to dietary supplements and adults to infants. J Nutr. 2000;130:654S–655S. doi: 10.1093/jn/130.3.654S. [DOI] [PubMed] [Google Scholar]
  • 29.Oitate M, Nakaki R, Koyabu N. Transcellular transport of genistein, a soybean-derived isoflavone, across human colon carcinoma cell line (Caco-2) Biopharm Drug Dispos. 2001;22:23–29. doi: 10.1002/bdd.253. [DOI] [PubMed] [Google Scholar]
  • 30.Wang RT, Zhou SY, Mei QB. Enzyme kinetics of genistein metabdism in rat liver microsomes. Chin J Clin Pharmacol Ther. 2005;10:294–297. [in Chinese] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES